Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q3 2024 Earnings Report

Xenetic Biosciences logo
$3.20 -0.04 (-1.20%)
As of 08/1/2025 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.61 million
Expected Revenue
$0.75 million
Beat/Miss
Missed by -$140.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Xenetic Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat